Search

Your search keyword '"Bayer AG -- Product development"' showing total 611 results

Search Constraints

Start Over You searched for: Descriptor "Bayer AG -- Product development" Remove constraint Descriptor: "Bayer AG -- Product development"
611 results on '"Bayer AG -- Product development"'

Search Results

1. Phase III ARANOTE trial of darolutamide plus ADT significantly reduced the risk of radiological progression or death compared to placebo plus ADT in patients with mHSPC

2. Bayer presents detailed results from OASIS 3 phase III study of elinzanetant to treat VMS associated with menopause at 2024 TMS meeting

3. Bayer to unveil new data from its phase III OASIS 3 long-term study of elinzanetant to treat vasomotor symptoms associated with menopause

4. Bayer initiates patient enrolment in phase III SOHO-02 trial of BAY 2927088 in non-small cell lung cancer

5. Findings from Tufts University Has Provided New Data on Clinical and Translational Science (Assessing the Net Financial Benefits of Employing Digital Endpoints In Clinical Trials)

6. Bayer is advancing in studies on heart failure management showcasing late-breaking heart failure data from phase III study FINEARTS-HF with finerenone

7. Bayer begins phase II study of soluble guanylate cyclase activator, BAY3283142 in patients with chronic kidney disease

8. Bayer initiates Phase II study of sGC activator in chronic kidney disease

9. Bayer submits NDA to US FDA for elinzanetant to treat moderate to severe VMS associated with menopause

10. Growing number of lifesciences GCCs underscores India's importance in R&D and clinical trials

11. Bayer initiates phase I study with novel targeted radionuclide therapy 225Ac-PSMA-Trillium in advanced metastatic prostate cancer

12. Bayer to present results from phase III OASIS 1 and 2 of elinzanetant to treat vasomotor symptoms associated with menopause at ACOG meeting

13. Bayer to present data from Kerendia trial program at Heart Failure 2024 Congress

14. Bayer to present new long-term results and subgroup analyses from pivotal clinical trial of Eylea 8 mg in nAMD & DME at ARVO meeting

15. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough

16. Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF [?]40% at AHA 2024

17. BAYER TO PRESENT NEW PRESPECIFIED SUBGROUP ANALYSES FROM INVESTIGATIONAL PHASE III FINEARTS-HF TRIAL IN PATIENTS WITH HEART FAILURE WITH LVEF Ae[yen]40% AT AHA 2024

18. Multiple Sclerosis Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion, Bayer, Acorda

19. Bayer announces positive results from phase III study OASIS 3 of elinzanetant for moderate to severe vasomotor symptoms

20. Bayer begins phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis

21. Bayer, AskBio announce first patient randomized in GenePHIT phase II trial of AB-1002 to treat congestive heart failure

22. Vividion begins patient dosing in phase I trial of oral STAT3 inhibitor, VVD-130850 to treat advanced solid and haematologic tumours

23. AskBio begins phase II GenePHIT trial of AB-1002 to treat congestive heart failure

24. Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

25. ESMO 2024 Late-Breaking Data: Phase III ARANOTE Trial Shows NUBEQA(r) (darolutamide) Significantly Reduced Risk of Radiological Progression or Death in Metastatic Hormone-Sensitive Prostate Cancer

26. Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

27. Data from Phase III study OASIS 3

28. Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause

29. Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause

30. BlueRock Therapeutics Reports FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001

31. Bayer to unveil new data from its Phase III OASIS 3 long-term study of elinzanetant in the treatment of vasomotor symptoms associated with menopause

32. Bayer to Unveil New Data From Its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated With Menopause

33. BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases

34. BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases

35. Bayer starts Phase III Trial in Non-Small Cell Lung Cancer (NSCLC)

36. ESC Congress 2024: Bayer to Present Phase III KERENDIA® (finerenone) Data

37. Bayer starts Phase III trial in non-small cell lung cancer (NSCLC)

38. Bayer is advancing in studies on heart failure management showcasing late-breaking heart failure data from Phase III study FINEARTS-HF with finerenone

39. Bayer Initiates Phase II Study Of Soluble Guanylate Cyclase Activator In Patients With Chronic Kidney Disease

41. The Journal of American Medical Association (JAMA) publishes Elinzanetant Phase III data

42. Bayer Initiates Phase II Study of Soluble Guanylate Cyclase Activator (BAY3283142) in Patients With Chronic Kidney Disease

43. Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint

44. Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint

45. Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint

46. AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease

47. AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease

48. Annovis Bio Greets Four New Executives to Strengthen Leadership Team

49. Interstitial Lung Disease Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

50. Hemophilia A Clinical Trials Assessment 2024: FDA Approvals, Pipeline, Therapies, Treatment Market and Companies by DelveInsight

Catalog

Books, media, physical & digital resources